The role of the gut microbiota in NAFLD

  title={The role of the gut microbiota in NAFLD},
  author={Christopher Leung and Leni Rose Rivera and John Barton Furness and Peter W. Angus},
  journal={Nature Reviews Gastroenterology \&Hepatology},
NAFLD is now the most common cause of liver disease in Western countries. This Review explores the links between NAFLD, the metabolic syndrome, dysbiosis, poor diet and gut health. Animal studies in which the gut microbiota are manipulated, and observational studies in patients with NAFLD, have provided considerable evidence that dysbiosis contributes to the pathogenesis of NAFLD. Dysbiosis increases gut permeability to bacterial products and increases hepatic exposure to injurious substances… 

Role and effective therapeutic target of gut microbiota in NAFLD/NASH.

A systematic summary of the characterization of gut microbiota and the significant association between the gut microbiome and non-alcoholic fatty liver disease was provided.

Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications

The gut microbiota dysregulation is a feature of NAFLD, and the signatures of gut microbiota are associated with the severity of the disease through altered bacterial metabolites.

Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives

The composition and characteristics of intestinal microbes are summarized and molecular insights into the intestinal microbiome in development and progression of NAFLD are reviewed and the potential mechanisms of “gut–liver axis” manipulation and efficacy of these therapeutic strategies forNAFLD treatment are discussed.

Current Research on the Pathogenesis of NAFLD/NASH and the Gut–Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome

This review summarizes recent research linking the gut microbiome to liver diseases, offering new research directions to elucidate the detailed mechanisms and novel targets for treatment and prevention.

The Gut Microbiota and its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.

The current evidence regarding the key role of the gut microbiota and its metabolites in the pathogenesis and development of NAFLD is highlighted, and the advances in the progression and applied prospects of gut microbiota-targeted dietary and exercise therapies are discussed.

Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD

During aging, altered composition of gut microbiota, along with circadian clock dysregulation, appears to contribute to increased incidence and/or severity of NAFLD.

Gut microbiome and microbial metabolites in NAFLD and after bariatric surgery: Correlation and causality

Characteristics of the gut microbiome in patients with NAFLD before and after BS are summarized and existing evidence about the underlying mechanisms of the Gut microbiome is accumulated.

Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut–liver axis

In conclusion, diet is among the main triggers of NAFLD and the gut microbiota is modified accordingly, underlining the importance of the concomitant study of the nutrients and microbial impact on liver health and metabolism, in order to propose innovative, clinically relevant, therapeutic approaches.

Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?

Recent randomized clinical trials suggest that probiotics/synbiotics could improve transaminases, hepatic steatosis, and reduce hepatic inflammation and further data is needed to unravel probiotic/ synbiotics efficacy, safety, and sustainability as a novel pharmacologic approaches to NAFLD.

Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification.

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease with prevalence rates that are on the rise in the US and worldwide. NAFLD encompasses a spectrum of liver pathologies including



Obesity, fatty liver disease and intestinal microbiota.

  • N. Arslan
  • Medicine, Biology
    World journal of gastroenterology
  • 2014
regulation of intestinal microbial ecosystem by diet modifications or by using probiotics and prebiotics as a treatment for obesity and its complications might be the issue of further investigations.

Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease

It is postulate that aside from dysbiosis of the gut microbiota, gut microbiota-mediated inflammation of the intestinal mucosa and the related impairment in mucosal immune function play an important role in the pathogenesis of NAFLD.

Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease.

Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence.

The Role of Nutrients in the Development, Progression, and Treatment of Nonalcoholic Fatty Liver Disease

The evidence-linking macronutrients (such as carbohydrates and fat in general and fructose, fiber, short chain fatty acids, polyunsaturated fatty, and choline specifically) and micronut nutrients ( such as vitamin E and C and minerals) with the development and treatment of NAFLD are discussed.

Targeting Dysbiosis for the Treatment of Liver Disease.

Mechanisms of dysbiosis-induced liver disease are examined; current knowledge regarding the role of Dysbiosis in nonalcoholic liver disease, alcoholic Liver disease, and cirrhosis is highlighted; and potential therapeutic targets are discussed.

Obesity, Diabetes, and Gut Microbiota

Following encouraging results in animals, several short-term randomized controlled trials showed the benefit of prebiotics and probiotics on insulin sensitivity, inflammatory markers, postprandial incretins, and glucose tolerance.

Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease.

Clinical trials on the use of probiotics in the treatment of nonalcoholic fatty liver disease are reviewed and the effects of these agents and their efficacy as an emerging therapeutic resource to treat NAFLD patients are discussed.

Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice

Multivariate statistical modeling of the spectra shows that the genetic predisposition of the 129S6 mouse to impaired glucose homeostasis and NAFLD is associated with disruptions of choline metabolism, and indicates that gut microbiota may play an active role in the development of insulin resistance.

Intestinal microbiota during infancy and its implications for obesity.

How the Gut microbiota regulates obesity and how environmental factors that affect the establishment of the gut microbiota during infancy may contribute to obesity later in life are discussed.